DECEMBER - 202019TECH OUTLOOKIt is well known that vaccine development workflows vary depending on the platform chosen (e.g. inactivated virus vs. RNA vaccine) and each has its own advantages. And, in all the steps of screening, SYNENTEC's imaging platforms support the laboratory work. It can either be the high-throughput screening for binding to virus-specific antibodies, immunogen engineering by CRISPR/Cas9, testing of the vaccine vector for transduction efficiency, SCC with verification of clonality, its subsequent growth control of the clones and determination of the high producers by titer assay, or final screening of the generated antigens by virus neutralisation tests to assess the efficacy of a vaccine. Thus, it brings the advantage of performing almost the entire screening workflow in vaccine development with only one device--reflecting a much more streamlined and faster workflow.What's more interesting is the underlying YT-image analysis software--the bedrock of both CELLAVISTA and NYONE solutions--for the storage, handling and processing of imaging data for documentation and presentation purposes. While CELLAVISTA and NYONE is used for data generation, YT-Software is used for analysing specific properties in cells or cell features, and the results are visualised using overlays in the software. Moreover, YT-Software is easy to handle and offers many possibilities for individual settings where necessary. "Our customers appreciate the extraordinarily precise and highly sensitive image cytometry of YT-Software as well as the use of automatable templates that increase reproducibility and eliminate human error. Above all, new functions and image processing operators are always made available to our customers free-of-charge," states Hummel.While several factors are consistently playing a significant role in SYNENTEC's continued success, the firm's core values and the team's work culture has always enabled them to rise above others. Today, many customers in the CLD area are riding the coattails of SYNENTEC's holistic offerings to get their workload under control or help in the field antibody detection, where SYNENTEC's sensitivity has enabled its customers to run their assays at the desired throughput.The company seeks to further strengthen its position by enhancing its offerings and making them more robust. To that end, the future of SYNENTEC can be characterised by capacity expansions. "We are currently close to the limits of our production capabilities and need to take the necessary action. And, geographically, are well-positioned in the U.S., Asia, and Europe for years," mentions Hummel. More importantly, the present times have substantiated the company's wide range of applications and earned them the position of being called `crisis-proof,' and "we wish to continue this way for helping pharma companies for not only immunology but also drug screening, high-content screening, and cell line development," concludes Hummel.
< Page 9 | Page 11 >